



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




Odevixibat

Item No. 35344

CAS Registry No.: 501692-44-0
Formal Name: (2S)-2-[[[(2R)-2-[[2-[[3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,2,5-benzothiadiazepin-8-yl]oxy]acetyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-butanoic acid

Synonym: A4250
MF: C₃₇H₄₈N₄O₈S₂
FW: 740.9
Purity: ≥90%
UV/Vis.: λ_{max}: 223, 281 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Odevixibat is supplied as a solid. A stock solution may be made by dissolving the odevixibat in the solvent of choice, which should be purged with an inert gas. Odevixibat is soluble in DMSO.

Description

Odevixibat is an inhibitor of the sodium/bile acid and sulfated solute cotransporter (ASBT; IC₅₀ = 0.16 nM).¹ It inhibits intestinal reabsorption of [⁷⁵Se]homotaurocholic acid (⁷⁵SeHCAT) by 74% in ApoE^{-/-} mice when administered at a dose of 0.156 μmol/kg. Formulations containing odevixibat have been used in the treatment of pruritis in patients with progressive familial intrahepatic cholestasis, an inborn error of metabolism characterized by mutations in various genes involved in bile production and transport, including *ATP8B1* and *ABCB11*.

Reference

1. Gillberg, P.-G., Graffner, H., and Ingemar, S. IBAT inhibitors for the treatment of liver disease. *Albireo AB*. US009694018B1 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM